Is There an Improvement on the Web Sites of the National and International Pharmaceutical Companies in Turkey? A Follow-Up Study

被引:1
|
作者
Yegenoglu, Selen [1 ]
Aslan, Dilek [2 ]
Sozen, Bilge [1 ]
机构
[1] Hacettepe Univ, Fac Pharm, Pharm Management Dept, TR-06100 Ankara, Turkey
[2] Hacettepe Univ, Fac Med, Dept Publ Hlth, TR-06100 Ankara, Turkey
关键词
pharmaceutical industry; Internet; follow-up studies; ADVERSE DRUG-REACTIONS; INFORMATION-SEEKING; HEALTH INFORMATION; INTERNET; WEBSITES;
D O I
10.1089/tmj.2011.0129
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: In this follow-up study, we aimed to assess national and international pharmaceutical companies' Web sites using guidelines of The Association of Research-Based Pharmaceutical Companies (AIFD) and Pharmaceutical Manufacturers Association of Turkey (IEIS) to define whether there has been progress since 2004. Materials and Methods: We used two national guidelines in order to evaluate the Web sites of pharmaceutical companies in our study. The first guideline was from IEIS, and the second was from AIFD, which was issued recently. We collected our data between February 1 and April 30, 2011. Data analyses were performed using SPSS version 15.0. Chi squared test was done for comparing the two assessments in different years (2004 and 2011). Results: In general, the progress that we were expecting was not satisfactory for both the international and national companies. The percentage of unmet criteria increased for "links" (from 48.0% to 52.0%) and for "mentioning the responsible person/firm for the Web site design" (from 40.6% to 59.4%) among national companies. We observed statistically significant progress only for the "information for the public" criterion (from 52.9% to 1000/u) among international companies. On the other hand, there was progress and a statistically significant difference in terms of not displaying any "drug ads" on the Web sites of national firms (from 55.9% to 87.5%), availability of "mail address" (from 88.2% to 100%), "telephone number" (from 88.2% to 100%), "indication of the target group" (from 23.5% to 52.1%), and "disclaimer stating the given information cannot replace a physician or pharmacist" (from 29.4% to 53.1%). Conclusions: Our major recommendation to pharmaceutical companies is to update their Web sites with evidence-based scientific information about themselves and their products using international and national standards. From the companies' perspective, this should be a priority responsibility based on the ethical aspect of individual and community health.
引用
收藏
页码:238 / 243
页数:6
相关论文
共 50 条
  • [1] What is missing on their web sites? An evaluation of national and international pharmaceutical companies in Turkey
    Yegenoglu, S
    Aslan, D
    Acar, A
    Calgan, Z
    [J]. TELEMEDICINE JOURNAL AND E-HEALTH, 2005, 11 (06): : 684 - 691
  • [2] Pharmaceutical companies information and antibiotic prescription patterns: A follow-up study in Spanish primary care
    Fernandez-Alvarez, Iria
    Zapata-Cachafeiro, Maruxa
    Vazquez-Lago, Juan
    Lopez-Vazquez, Paula
    Pineiro-Lamas, Maria
    Garcia Rodriguez, Raquel
    Figueiras, Adolfo
    Estany Gestal, Ana
    Caamano, Francisco
    Gestal-Otero, Juan J.
    Taracido, Margarita
    Lopez-Duran, Ana
    Salgado, Angel
    Lopez Gonzalez, Elena
    Sastre, Isabel
    [J]. PLOS ONE, 2019, 14 (08):
  • [3] Web citation availability - A follow-up study
    Casserly, Mary F.
    Bird, James E.
    [J]. LIBRARY RESOURCES & TECHNICAL SERVICES, 2008, 52 (01): : 42 - 53
  • [4] National, corporate, and professional identities in international pharmaceutical companies
    Miller, R
    [J]. CANADIAN JOURNAL OF INFORMATION AND LIBRARY SCIENCE-REVUE CANADIENNE DES SCIENCES DE L INFORMATION ET DE BIBLIOTHECONOMIE, 2003, 27 (04): : 80 - 80
  • [5] Usability of American Nurses Association State Web Sites A Follow-up Evaluation
    Koch, Gina
    Wakefield, Bonnie J.
    Alexander, Gregory L.
    Wilson, Melissa A.
    Becker, Colleen
    [J]. CIN-COMPUTERS INFORMATICS NURSING, 2016, 34 (05) : 215 - 223
  • [6] Loss to follow-up in an international, multicentre observational study
    Mocroft, A.
    Kirk, O.
    Aldins, P.
    Chies, A.
    Blaxhult, A.
    Chentsova, N.
    Vetter, N.
    Dabis, F.
    Gatell, J.
    Lundgren, J. D.
    [J]. HIV MEDICINE, 2008, 9 (05) : 261 - 269
  • [7] Follow-up after gastrectomy for cancer: Results of an international web round table
    Baiocchi, Gian Luca
    Kodera, Yasuhiro
    Marrelli, Daniele
    Pacelli, Fabio
    Morgagni, Paolo
    Roviello, Franco
    De Manzoni, Giovanni
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (34) : 11966 - 11971
  • [8] Follow-up after gastrectomy for cancer:results of an international web round table
    Gian Luca Baiocchi
    Yasuhiro Kodera
    Daniele Marrelli
    Fabio Pacelli
    Paolo Morgagni
    Franco Roviello
    Giovanni De Manzoni
    [J]. World Journal of Gastroenterology, 2014, (34) : 11966 - 11971
  • [9] A follow-up study on the effects of an educational intervention against pharmaceutical promotion
    Civaner, M. Murat
    [J]. PLOS ONE, 2020, 15 (10):
  • [10] HIV PATIENT SELECTION FOR PHARMACEUTICAL FOLLOW-UP
    Ibarra Barrueta, Olatz
    Gabilondo Zelaia, Itxasne
    Mora Atorrasagasti, Oihana
    [J]. ATENCION FARMACEUTICA, 2009, 11 (02): : 95 - +